Home » Entries posted by pharmanewsdaily
Entries posted by pharmanewsdaily
Cancer immunotherapy company EpicentRx raises $35m in Series D round

Cancer immunotherapy company EpicentRx raises $35m in Series D round

EpicentRx, a cancer immunotherapy company based in California, has secured $35 million of capital through a Series D financing round to support the development of small molecule immunotherapy and its oncolytic viral platform. The oncology company used the services of Biotech Alliances International, a Silicon Valley based life-science focused investment bank to get the funding. […]

ProteKt secures funding for PKR kinase inhibitor-based therapies

Israeli biotech company ProteKt Therapeutics, which is focused on developing new PKR kinase inhibitor-based therapies for Alzheimer’s Disease and other neurodegenerative diseases, has secured $3.6 million in post-incubation financing. The financing was led jointly by Canadian capital development fund Fonds de solidarité FTQ and South Korean pharma company Bukwang Pharmaceutical. Existing investors – FutuRx, OrbiMed, […]

Continue reading …
Novartis’ Sandoz to acquire Aspen’s Japanese pharma business

Sandoz, the generic drug business of Novartis has agreed to acquire the Japanese business of Aspen Global Incorporated (AGI), a fully owned subsidiary of Aspen Pharmacare in a deal valued up to €400 million, as per the latest pharma acquisition news. The acquisition includes shares in Aspen Japan and associated assets held by the South […]

Continue reading …
F2G gets olorofim breakthrough therapy status from FDA for mold infection

F2G has secured breakthrough therapy designation to olorofim (formerly F901318) from the US Food and Drug Administration (FDA)  for the treatment of invasive mold infections. The breakthrough therapy designation is for the use of olorofim in patients having limited or no treatment options, and also those who are intolerant to currently available therapy for their […]

Continue reading …
Chinese biopharma company Akeso raises $150m for antibody drug discovery

Akeso, a Chinese biopharma company engaged in antibody drug discovery and development in oncology and immunology therapeutic areas, has raised nearly $150 million through a Series D funding round. The investment in the clinical stage company was led by Loyal Valley Capital (LVC) and Sino Biopharmaceutical. The co-investors in the Series D round are healthcare […]

Continue reading …
Celgene, Acceleron bag Reblozyl FDA approval for anemia in beta thalassemia

Reblozyl FDA approval : Celgene and Acceleron Pharma have bagged approval from the US Food and Drug Administration (FDA) for Reblozyl (luspatercept-aamt) for the treatment of anemia associated with beta thalassemia in adults who need regular red blood cell (RBC) transfusions. Reblozyl is now the first and only erythroid maturation agent to be approved by […]

Continue reading …
WIRB-Copernicus acquires clinical trial consultant Waife & Associates

WIRB-Copernicus Group (WCG), a clinical services organization, said that its clinical services division has acquired Waife & Associates (W&A), a provider of management consulting services for biopharma clinical research clients. Financial terms of the acquisition were not disclosed by the parties. Waife & Associates is engaged in making clinical development more efficient and productive by […]

Continue reading …
Yuhan Pharmaceuticals to use Cyclica’s AI-driven drug discovery platform

Yuhan Pharmaceuticals has entered into a collaboration with Canadian biotechnology company Cyclica to use the latter’s artificial intelligence (AI) driven integrated drug discovery platform in two separate research and development (R&D) programs in oncology. The South Korean healthcare company said that it is looking to adopt innovative technologies to boost its drug development efforts. In […]

Continue reading …
Takeda Pharmaceutical opens €130m vaccine manufacturing plant in Germany

Takeda Pharmaceutical Company opened a new €130 million vaccine manufacturing plant in Germany at Singen to produce TAK-003, its dengue vaccine candidate. The Singen vaccine manufacturing facility will be used for the formulation, fill, finish and secondary packaging of the TAK-003 dengue vaccine candidate starting with the packaging line. The vaccine plant employs up to […]

Continue reading …
Amgen to take 20.5% stake in Chinese biotech company BeiGene for $2.7bn

US biopharma company Amgen has signed an all-cash deal to acquire a 20.5% stake in Chinese biotech company BeiGene for about $2.7 billion, as per the latest pharma acquisition news. The Beijing-based BeiGene is a research-based, oncology-focused biotechnology company, which is engaged in developing molecularly targeted and immuno-oncology drug candidates for cancer treatment. The transaction […]

Continue reading …
Page 1 of 96123Next ›Last »